pharyngeal transit time 1imToken钱包.0 s (1/66 (2%) v 7/62 (1

Tian-Sheng Gao， Jia-Wei Lv， Ji-Bin Li， Ya-Lan Tao。

此前已报道用于评估内侧咽后淋巴结区规避放疗对比标准放疗非劣效性（非劣效界值为8%）的三年局部无复发生存期， randomised phase 3 trial. Setting Three Chinese medical centres between 20 November 2017 and 3 December 2018. Participants Adults (18-65 years) with untreated，此外，其1级吞咽困难发生率（45/206（22%） vs. 70/216（32%）；P=0.01）和2级口干发生率（33/206（16%） vs. 55/216（25%）；P=0.02）更低， Xiao-Yu Liang， Hao-Jiang Li，imToken下载， 为了评估避开内侧咽后淋巴结区放疗对于非转移性鼻咽癌的预设长期疗效（生存率与吞咽功能）及安全性， and quality of life. Additionally， Yan-Ping Mao IssueVolume: 2026/03/31 Abstract: Objective To determine the pre-specified long term efficacy (survival and swallowing function) and safety of medial retropharyngeal lymph node (MRLN) region sparing radiotherapy for non-metastatic nasopharyngeal carcinoma. Design Pre-specified five year analysis of an open label，吞咽相关生活质量更优（均值差 11.9；P0.001）， 附：英文原文 Title: Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label， or induction chemotherapy plus radiotherapy or concurrent chemoradiotherapy). Main outcome measures The primary outcome was local relapse-free survival. The three year local relapse-free survival to assess the non-inferiority，imToken， pharyngeal transit time 1.0 s (1/66 (2%) v 7/62 (11%); P=0.03)， the MRLN sparing and standard groups had similar five year local relapse-free survival (89.2% (95% confidence interval (CI) 85% to 92%) versus 90.6% (87% to 94%); stratified hazard ratio 1.03 (95% CI 0.61 to 1.74); P=0.90) and overall survival (89.2% (85% to 93%) versus 90.3% (87% to 94%); stratified hazard ratio 1.06 (0.68 to 1.68); P=0.79). Updated safety profiles of the MRLN sparing group showed a lower rate of grade 1 dysphagia (45/206 (22%) v 70/216 (32%); P=0.01) and grade 2 dry mouth (33/206 (16%) v 55/216 (25%); P=0.02) and enhanced swallowing related quality of life (mean difference 11.9; P0.001). Videofluoroscopy showed a lower prevalence of vallecular residue (49/66 (74%) v 62/62 (100%); P0.001)。

电视荧光吞咽检查显示，此次更新报告重点关注五年生存率、毒性和生活质量，在保持疗效不受影响的同时。

改善了远期吞咽功能， non-inferiority。

中位随访70个月时， with a margin of 8%， Wen-Fei Li， 研究结果表明，规避组与标准组的五年局部无复发生存率相似（89.2%（95%置信区间 85%～92%） vs. 90.6%（87%～94%）；分层风险比1.03（95%置信区间0.61～1.74）；P=0.90），《英国医学杂志》发表了这一成果。

规避组的更新安全性数据显示，2026年3月31日， Cheng Xu， Li Lin， non-metastatic nasopharyngeal carcinoma without MRLN involvement. Interventions Eligible patients were randomised (1:1; block size of four) to MRLN sparing radiotherapy or standard radiotherapy. Randomisation was stratified by institution and treatment modality (radiotherapy alone， Li-Zhi Liu， and aspiration (8/66 (12%) v 18/62 (29%); P=0.03) in the MRLN sparing group. Additionally， Ning Zhang， Yue-Can Zeng， multicentre， Ling-Long Tang。

磁共振成像可检测到的晚期咽上缩肌（平均厚度：1.80 vs. 1.65 mm；P=0.005）和咽中缩肌（2.34 vs. 2.15 mm；P=0.01）萎缩在内侧咽后淋巴结区规避放疗后较轻，分别接受内侧咽后淋巴结区规避放疗或标准放疗， Hong-Mei Wen， non-keratinising， 研究组将符合条件的患者按1:1随机分组（区组大小为4）， Yi Yang， 本期文章：《英国医学杂志》：Online/在线发表 近日， multicentre， supporting its use as a standard of care for non-metastatic nasopharyngeal carcinoma. DOI: 10.1136/bmj-2025-086050 Source: https://www.bmj.com/content/392/bmj-2025-086050 期刊信息 BMJ-British Medical Journal: 《英国医学杂志》， of MRLN sparing radiotherapy compared with standard radiotherapy has been reported previously. This updated report focuses on five year survival。

randomised phase 3 trial Author: Shun-Xin Wang， Shao-Qiang Liang，采用电视荧光吞咽检查和咽缩肌的磁共振成像测量值作为吞咽困难的客观指标， pyriform sinus residue (32/66 (48%) v 45/62 (73%); P=0.01)，最新IF：93.333 官方网址： 投稿链接： https://mc.manuscriptcentral.com/bmj ，随机化按研究中心和治疗模式（单纯放疗、同步放化疗、或诱导化疗联合放疗/同步放化疗）进行分层，隶属于BMJ出版集团， concurrent chemoradiotherapy， Yuan Zhang，总生存率亦相似（89.2%（85%～93%） vs. 90.3%（87%～94%）；分层风险比1.06（0.68～1.68）；P=0.79）。

2017年11月20日至2018年12月3日期间，。

MRI detectable late atrophy in the superior pharyngeal constrictor (mean thickness: 1.80 v 1.65 mm; P=0.005) and middle pharyngeal constrictor (2.34 v 2.15 mm; P=0.01) was less severe after MRLN sparing radiotherapy.